---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-064531"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T12:46:25.807128+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Prelude Q1 2025 net loss $32.1M; cash $103.1M funds ops into Q2 2026

## Summary
- Cash, cash equivalents, restricted cash and marketable securities of $103.1M as of March 31, 2025.
- Net loss of $32.1M ($0.42 per share) vs. $31.4M ($0.42) in Q1 2024; R&D expense $28.8M (+5% YoY).
- PRT3789 monotherapy and docetaxel combo dose escalation complete; Phase 2 data expected H2 2025.
- PRT7732 Phase 1 advancing in 5th cohort at 60 mg once daily; initial data anticipated H2 2025.
- KAT6A degrader program targeting candidate nomination in Q2 2025 and IND in 2026.

## SEC filing metadata
- accession: 0000950170-25-064531
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000095017025064531/0000950170-25-064531-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000095017025064531/prld-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-064531
- JSON: https://secwatch.observer/filing/0000950170-25-064531.json
- Plain text: https://secwatch.observer/filing/0000950170-25-064531.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.